Basel, Switzerland – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today statistically significant and clinically meaningful results from the phase III INShore study of Gazyva®/Gazyvaro® (obinutuzumab) in children and young adults (aged >= 2-25 years) with idiopathic nephrotic syndrome (INS). The study met its primary endpoint, with more people achieving...
Latest News
Basel, Switzerland – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today three-year follow-up data from the pivotal phase III STARGLO study in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of therapy and are not candidates for autologous stem...
Updated data from the pivotal phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a 40% survival benefit for people with R/R DLBCL who are not candidates for transplant1 89% of patients whose cancer had fully responded at the end of treatment with Columvi in combination...
BASEL, Switzerland – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the Phase IIIMETEOROID study demonstrating that ENSPRYNG® (satralizumab) reduced the risk of a new relapse by 68% compared to placebo in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), meeting its primary endpoint. The...
Basel – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Evrysdi™ (risdiplam) for the treatment of 5q spinal muscular atrophy (SMA) in patients two months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with...
Basel – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced new 2-year data from Part 2 of FIREFISH, a Phase 2/3 global study evaluating Evrysdi™ (risdiplam) in infants aged 1-7 months at enrollment with symptomatic Type 1 spinal muscular atrophy (SMA). The data showed Evrysdi continued to improve motor function between...
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with SMA Evrysdi offers the same efficacy and safety demonstrated in available oral solution Evrysdi is the only non-invasive disease-modifying SMA treatment, with more than 18,000 people with SMA treated globally to date Basel, Switzerland –...
Basel, Switzerland – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib met its primary endpoint of non-inferiority compared to OCREVUS (ocrelizumab) in reducing disability progression in patients with primary progressive multiple sclerosis...
Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two years of treatment Phase III studies for fenebrutinib in relapsing and primary progressive multiple sclerosis are expected to start reading out at year end Basel, Switzerland – Roche (SIX: RO,...
Basel, Switzerland – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the first Phase III (FENhance 2) of two pivotal, similarly-designed Phase III studies (FENhance 1 and 2) in patients with relapsing multiple sclerosis (RMS) met its primary endpoint. Fenebrutinib, an investigational Bruton’s tyrosine kinase (BTK) inhibitor, significantly reduced...